REDWOOD CITY, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that it will present at the Roth 20th Annual OC Growth Stock Conference on Tuesday, February 19, 2008 at 9:00 a.m. Pacific Time . Russell Howard, Maxygen's chief executive officer, will present. A live webcast of the presentation can be accessed on Maxygen's website at http://www.maxygen.com/webcasts. A replay of the presentation will be available until March 19, 2008 .

About Maxygen

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. The company's lead program, MAXY-G34, is designed to be an improved version of PEG-GCSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in Maxygen's pipeline is a new Factor VIIa product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis. Maxygen uses its proprietary DNA shuffling technology and extensive protein modification expertise to pursue the creation of biosuperior proteins. http://www.maxygen.com

SOURCE Maxygen, Inc.